Lantheus Medical Imaging taps Orlandi as next CMO

Editorial Staff | | Health Imaging | Molecular Imaging

Lantheus Medical Imaging has appointed Cesare Orlandi, MD, to serve as its next chief medical officer (CMO).

Orlandi is charged with leading the company’s clinical development, medical affairs, pharmacovigilence and regulatory affairs, as well as overseeing its Phase 3 clinical trial program for flurpiridaz F 18. The new CMO will report directly to Jeff Bailey, president and CEO.

“Cesare’s versatile and cross-functional experience with leading clinical programs and product life cycle management will bring significant benefits to our company,” Bailey said in a statement.

Orlandi most recently served as senior vice president and CMO of TransTech Pharma, and also held the roles of senior vice president and CMO of Cardiokine, and vice president as Otsuka Pharmaceuticals. He received his medical degree from the University of Pavia Medical School in Pavia, Italy.

Orlandi currently serves as adjunct assistant professor of medicine at Tufts University School of Medicine in Boston.

 

Editorial Staff

Related Content

Researchers receive grant worth millions to develop portable PET scanner
Why is the US still dependent on foreign medical isotope production?
Downed high-flux reactor could restart sooner than anticipated
Some nuc med departments are already feeling the strain of the isotope shortage
NorthStar opens facility to assist with development and distribution of vital radioisotopes
Lizard saliva could be key to spotting elusive pancreatic tumors

Around the web

Cardiovascular Business
Positron partners with Upbeat Cardiology Solutions to improve cardiac PET/CT access

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.